Fractyl Labs Raises $40M Series C To Develop Diabetes Treatments

 Fractyl Labs, which develops treatments for diabetes, has raised a $40 million Series C round led by Mithril, with participation from returning investors General Catalyst, Bessemer Venture Partners, and Domain Associates. The new capital will be used to fund clinical evaluation of a procedure that Fractyl has developed. Read More
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.